FBIO 250117 2.50C (FBIO250117C2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

FBIO250117C2500

Watchlist

0.14
0.000.00%

15min DelayClose Jan 6 16:00 ET

0.15High0.10Low

Intraday

5D
Daily

News

Fortress Biotech's Cyprium Therapeutics Receives Priority Review for CUTX-101 New Drug Application With Target Action Date of June 30, 2025
Quiver QuantitativeJan 6 08:14 ET
Express News | Fortress Biotech Inc - FDA Sets Pdufa Target Action Date for Cutx-101 on June 30, 2025
ReutersJan 6 08:00 ET
Express News | Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Cutx-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease
ReutersJan 6 08:00 ET
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 29% But Its Business Still Trails The Industry
Simply Wall StDec 28, 2024 07:07 ET
Express News | Checkpoint Therapeutics Announces FDA Approval of Unloxcyt™ (Cosibelimab-Ipdl)
ReutersDec 13, 2024 18:15 ET
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (Cosibelimab-ipdl)
GlobeNewswireDec 13, 2024 18:15 ET

Comments

Jaguar8

15 hours ago

NEWS

$Fortress Biotech (FBIO.US)$
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Monday, 6th January at 8:00 am
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025
Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones
Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA appro...

Jaguar8

Dec 13, 2024 18:10

🕛Watchlist MONDAY December 16. NFA. Trade the chart. Be kind… in progress

$Gorilla Technology (GRRR.US)$ PR: CEO will have interview with Red Chip Small Stock, Big Money show on Sat Dec 14. Reports on CEO on X that they have been selected from the shortlist for the $438M deal in SE Asia. Low float. $23.2M cash good for 12 months
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...

Jaguar8

Dec 13, 2024 17:49

I already gave you my initial Monday Watchlist. I’ll post the complete one Sunday.

my open positions
$Checkpoint Therapeutics (CKPT.US)$
$Gorilla Technology (GRRR.US)$ $Fortress Biotech (FBIO.US)$ $Tonix Pharmaceuticals (TNXP.US)$

Jaguar8

Dec 13, 2024 17:36

This is good for MONDAY for me. NFA

$Fortress Biotech (FBIO.US)$

Jaguar8

Dec 13, 2024 17:16

NEWS

$Fortress Biotech (FBIO.US)$
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
19 seconds ago, 3:15 PM PST
Via GlobeNewswire
CKPTFBIO
Share
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma ("cSCC") or locally advanced c...